Keyphrases
Non-small Cell Lung Cancer (NSCLC)
61%
Non-small Cell Lung Cancer Patients
47%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
40%
Vinorelbine
40%
ERCC1
37%
Cisplatin
37%
Malignant Pleural Mesothelioma
37%
TUBB3
37%
Carboplatin
30%
Tumor
27%
Paclitaxel
27%
Immunohistochemistry
25%
Pharmacology & Toxicology
25%
Chemotherapy
20%
Diagnostic Biopsy
20%
Protein Expression
18%
MRNA Expression
18%
Quantitative PCR
18%
Biopsy Specimen
17%
Progression-free Survival
17%
Quality of Life
17%
Resection Specimen
16%
Randomized Trial
15%
Tubulin
15%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Neoplasm
45%
Base Excision Repair
37%
Biopsy Technique
33%
Carboplatin
32%
Paclitaxel
31%
Protein Expression
28%
Surgery
26%
Cisplatin
26%
Diagnosis
26%
Primary Tumor
25%
Vinorelbine
25%
Malignant Neoplasm
25%
Exon
18%
Messenger RNA
17%
Neoadjuvant Chemotherapy
17%
Hazard Ratio
15%
Immunohistochemistry
15%
Progression Free Survival
15%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
66%
Chemotherapy
41%
Cisplatin
28%
Pharmacokinetic
25%
Safety Pharmacology
25%
Toxicology
25%
Vitamin D-Binding Protein
25%
Pleura Mesothelioma
25%
Adenocarcinoma
23%
Neoplasm
22%
Overall Survival
22%
Progression Free Survival
19%
Carboplatin
15%